Dishman Carbogen Amcis Limited (NSE:DCAL)

Market Cap	23.91B -46.3%
Revenue (ttm)	29.01B +0.2%
Net Income	161.60M -84.5%
EPS	1.03 -84.7%
Shares Out	156.78M
PE Ratio	148.83
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	75,090
Open	153.86
Previous Close	153.57
Day's Range	151.30 - 153.90
52-Week Range	128.50 - 306.00
Beta	0.65
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About Dishman Carbogen Amcis

Dishman Carbogen Amcis Limited provides contract development and manufacturing organization (CDMO) services for the pharmaceutical and healthcare industries worldwide. It operates through Integrated CDMO Platform and Marketable Molecules segments. The company offers cholesterol and vitamin D analogs; soft gel capsules and formulations; intermediate and active pharmaceutical ingredients (APIs) which cover specific therapeutic areas, such as anesthetics, and contrast media agents for diagnostics, ophthalmic treatments, laxatives, and organophosph...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1983
• Employees: 934
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: DCAL

Financial Performance

In fiscal year 2026, Dishman Carbogen Amcis's revenue was 29.32 billion, an increase of 8.13% compared to the previous year's 27.12 billion. Earnings were 974.50 million, an increase of 2907.72%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 7, 2026

Data Sources Report a data error